Zoetis Inc. $ZTS Shares Sold by Elk River Wealth Management LLC

Elk River Wealth Management LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 40.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 17,183 shares of the company’s stock after selling 11,486 shares during the period. Elk River Wealth Management LLC’s holdings in Zoetis were worth $2,157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Nordea Investment Management AB increased its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the period. Seilern Investment Management Ltd increased its holdings in shares of Zoetis by 361.2% during the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after purchasing an additional 261,155 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after purchasing an additional 935,432 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after purchasing an additional 18,040 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Citigroup lowered their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Bank of America raised their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $134.75.

Zoetis Trading Up 0.9%

Shares of ZTS stock opened at $79.64 on Thursday. The stock has a 50-day simple moving average of $109.69 and a 200 day simple moving average of $119.37. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The stock has a market capitalization of $33.39 billion, a P/E ratio of 13.21, a P/E/G ratio of 1.29 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the business earned $1.48 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.